Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Shanghai Junshi Bioscience Co: Clinical Trials & FDA Approval Profile

Shanghai Junshi Bioscience Co (Global / Institutional) sponsors 59 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 25 active protocols (16 recruiting now), 27 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)10.2%
Median Closed Enrollment vs National (145 pts)183 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shanghai Junshi Bioscience Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)59
Active Pipeline (Recruiting Now)25 (16)
Completed vs Stopped Early27 / 6 (10.2%)
Median Closed Actual Enrollment183 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shanghai Junshi Bioscience Co
Hospital Research SiteLocationShared Protocols
Beijing Cancer HospitalBeijing, Beijing Municipality11
Harbin Medical University Cancer HospitalHarbin, Heilongjiang9
The Affiliated Hospital of Qingdao UniversityQingdao, Shandong8

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shanghai Junshi Bioscience Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06954467JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaPhase IIRECRUITING
NCT07876557A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negativePhase IIRECRUITING
NCT06095583Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell LuPhase IIIRECRUITING
NCT07284134JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.Phase IIIRECRUITING
NCT07045311JS207 Combination Therapy in Triple-negative Breast CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Junshi Bioscience Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI